Avisar Nitzan, Heller Yael, Weil Clara, Ben-Baruch Aviva, Potesman-Yona Shani, Oren Ran, Chodick Gabriel, Shalev Varda, Ash Nachman
Central District, Maccabi Healthcare Services, Yoni Netanyahu 5/31, Petach Tikva, Israel.
Medical Division, Maccabi Healthcare Services, Tel Aviv, Israel.
Isr J Health Policy Res. 2017 Sep 28;6(1):46. doi: 10.1186/s13584-017-0172-1.
In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel's national basket of health services. During 2015, HCV genotype 1 patients with advanced liver fibrosis (stage F3-F4) were eligible for treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir (OMB/PTV/r + DSV) provided through the four national health plans. As all health plans committed to identifying eligible patients nationwide, risk-sharing agreements created an additional incentive to develop an innovative model for rapid treatment delivery.
This article aims to describe the development and implementation of a multi-disciplinary patient-centered model for the expedited provision of costly therapies in a community setting, based on experience delivering new HCV therapy in 2015.
We present the case of the Central District in Maccabi Healthcare Services (MHS), one of five districts in a 2-million-member healthcare provider. We describe the dimensions of the model and its implementation, including the composition and responsibilities of the multi-disciplinary team, screening for patient eligibility, provision of care, and barriers and facilitators identified at each stage.
The experience of the MHS Central District indicates that good communication between all stakeholders was the key driver of successful implementation of the model. Overall, monthly treatment uptake increased following the intervention and by the end of 2015 a total of 99 patients were treated with OMB/PTV/r + DSV in this district. Early data indicate high effectiveness in this population and evaluation in ongoing.
This multi-disciplinary patient-centered model enabled rapid integration of screening and disease staging to identify and treat eligible HCV patients in the MHS central district. The model forms the basis of the 2017 project to deliver DAAs according to broader health basket criteria and may be adapted for the provision of other innovative health technologies in different healthcare settings.
2015年1月,首款用于慢性丙型肝炎病毒(HCV)感染的无干扰素直接抗病毒(DAA)疗法获批纳入以色列国家医疗服务项目。2015年期间,患有晚期肝纤维化(F3 - F4期)的HCV 1型患者有资格通过四项国家医疗计划接受ombitasvir/paritaprevir/ritonavir和达沙布韦(OMB/PTV/r + DSV)治疗。由于所有医疗计划都致力于在全国范围内识别符合条件的患者,风险分担协议为开发快速治疗交付的创新模式提供了额外激励。
本文旨在基于2015年提供新的HCV治疗的经验,描述一种以患者为中心的多学科模式在社区环境中快速提供昂贵疗法的开发与实施情况。
我们介绍了麦卡比医疗服务公司(MHS)中区的案例,MHS是一家拥有200万会员的医疗服务提供商的五个区之一。我们描述了该模式的各个方面及其实施情况,包括多学科团队的组成和职责、患者资格筛查、护理提供以及在每个阶段识别出的障碍和促进因素。
MHS中区的经验表明,所有利益相关者之间的良好沟通是该模式成功实施的关键驱动力。总体而言,干预后每月的治疗接受量有所增加,到2015年底,该地区共有99名患者接受了OMB/PTV/r + DSV治疗。早期数据表明该人群治疗效果良好,评估工作正在进行中。
这种以患者为中心的多学科模式能够快速整合筛查和疾病分期,以识别和治疗MHS中区符合条件的HCV患者。该模式构成了2017年根据更广泛的医疗服务标准提供DAA项目的基础,并且可能适用于在不同医疗环境中提供其他创新医疗技术。